HOME >> BIOLOGY >> NEWS
FDA approves Raptiva (efalizumab) for chronic moderate-to-severe plaque psoriasis

South San Francisco, CA, and Berkeley, CA Genentech, Inc. (NYSE: DNA) and XOMA Ltd. (Nasdaq: XOMA) announced today that RAPTIVA (efalizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. RAPTIVA is the first biologic therapy that is designed to provide continuous control of chronic moderate-to-severe plaque psoriasis and can be self-administered by patients as a single, once-weekly, subcutaneous injection.

"Today's FDA approval of RAPTIVA underscores our commitment to delivering innovative therapies to patients with unmet medical needs," said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer. "Through our collaboration with XOMA, the clinical trial investigators and most importantly, the over 2,700 patients who participated in our clinical trials, we are proud to offer a new therapeutic option to help patients manage this chronic disease."

"RAPTIVA represents XOMA's first product approval and is the culmination of a highly successful collaboration with Genentech," said John L. Castello, XOMA's chairman, president and chief executive officer. "The companies have worked together on a robust clinical program that has demonstrated the safety and efficacy of RAPTIVA. We view RAPTIVA now being available to
patients as a worthy testament to the confidence of our shareholders and the hard work and support of both companies'
employees."

"I've been treating psoriasis for over 15 years and have always been frustrated by the limited options available to treat patients with this chronic disease. Safety limitations of traditional therapies have made it difficult to offer patients continuous relief," said Craig Leonardi, M.D., clinical associate professor of dermatology of Saint Louis University, St. Louis, Mo. and a RAPTIVA clinical investigator. "RAPTIVA
'"/>

Contact: Emmy Tsui
emmy.tsui@ketchum.com
585-256-0195
Ketchum
27-Oct-2003


Page: 1 2 3 4 5 6

Related biology news :

1. FDA approves VYTORIN, first and only to powerfully reduce LDL cholesterol through dual inhibition
2. European Commission approves Herceptin + Taxotere as 1st-line therapy in HER2-positive breast cancer
3. FDA approves Abbotts Biaxin XL (clarithromycin extended-release tablet)for community-acquired pneumonia
4. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia
5. DFG approves 14 new research training units
6. National Science Board approves five new NSF Science and Technology Centers
7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
8. Results from open-label Raptiva study suggest continued benefit with long-term treatment
9. Genes appear to play a role in development of chronic obstructive pulmonary disease
10. New research supports theory that indirect transmission of chronic wasting disease
11. Animal studies show promise treating severe chronic pain

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2019)... , ... February 21, 2019 , ... Clean label food ... expected when creating natural foods and beverages. It is quite common to spot consumers ... Yet, meat products are not immune to this label scrutiny. , More than ...
(Date:2/19/2019)... ... February 20, 2019 , ... ... that will see Dimensions rolled out across the organization. Dimensions provides in-depth ... across their business, support strategic planning, and understand past and future funding ...
(Date:2/14/2019)... ... February 14, 2019 , ... This year’s conference in ... 80 scientific sessions and 2,100 presentations. Given SOT’s mission to bring together researchers ... OpenLiver™ 3D cell culture model initiative that it recently launched with Biopredic ...
Breaking Biology News(10 mins):
(Date:2/2/2019)... ... ... Stay on top of current hot topics through free webinars presented by leading ... free, so be sure to register today to save your place! Participate in the ... our upcoming webinars, or click below to learn more about each webinar: , CLINICAL ...
(Date:1/30/2019)... ... January 29, 2019 , ... Could a computer detect a ... tricky math problem on an online tutoring program? Could it detect deep reflection ... science assistant professor Erin Solovey is working to develop a system ...
(Date:1/24/2019)... ... ... Controlled Contamination Services is pleased to announce three exciting new additions to ... team members will support its growing operation across the US and will be a ... This addition will enable CCS to widen its reach and provide enterprise wide solutions ...
(Date:1/20/2019)... ... January 16, 2019 , ... On January 15 of ... news article by Asymmetrex director James L. Sherley, M.D., Ph.D. The ... resources like the PGCB and CellTrials.org. Now in its 21st year of operation, ...
Breaking Biology Technology:
Cached News: